The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...
Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...
Hosted on MSN6mon
Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming MarketRoche Holding AG (OTC:RHHBY) reportedly turned down a potential blockbuster weight-loss pill in 2018, allowing Eli Lilly And Co (NYSE:LLY) to acquire the drug, now known as orforglipron ...
Hosted on MSN7mon
Roche Jumps After Weight-Loss Pill Shows Promise in Study(Bloomberg) -- Roche Holding AG shares jumped after its experimental weight loss pill showed meaningful weight reduction in an early stage study among obesity patients, setting up the Swiss ...
In an interview with pharmaphorum, Marius Scholtz, country medical lead for Roche UK, said the drug will have around the same yearly cost in relapsing disease as Novartis’ once-daily pill ...
Roche has reported early-stage clinical data ... The new results are from a phase 1 trial of a once-daily pill called CT-966, which revealed an average weight loss of 7.3% at four weeks in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback